Purpose:
To evaluate quantitative functional ultrasonography (US) in a murine gel model by using microbubble destruction kinetics to determine whether parametric indices provided with US could help assess angiogenesis.
Materials And Methods:
Institutional Animal Subjects Committee approved experiments and procedures. In 36 normal mice, two 0.4-mL gel implants were placed subcutaneously on either side of spine. One implant contained 0.5, 1.0, or 1.5 microg human basic fibroblast growth factor (bFGF) per milliliter of gel. Functional US quantitative analysis of angiogenesis with microbubble contrast agent was performed on days 3, 6, 9, and 12; histologic data were collected. Time-intensity curve of implant was fitted to mathematic decay model to calculate fractional blood volume and fraction of blood replaced per unit of time. Microvascular density (MVD) and percentage of microvascular area (MVA) were measured after anti-CD31 staining. Spearman rank order correlation was used in analyses.
Results:
bFGF-containing implants induced MVD of eight, 35, 42, and 42 vessels per square millimeter on days 3, 6, 9, and 12, respectively; in controls, MVD was four vessels/mm2 (P<.05 on days 6, 9, and 12). bFGF-containing implants induced percentage MVA of 2%, 5%, 20%, and 27%, respectively; in controls, it was 0.5% (P<.05). Maximum enhancement was significantly increased in bFGF implants (23.3 gray level+/-14.1 [standard deviation]) compared with controls (11.0+/-5.5, P<.001). Implants containing bFGF showed poor correlations between fractional blood volume and MVD (r2=0.42) or percentage MVA (r2=0.51) at US. There was no correlation between microbubble velocity and MVD (r2<0.05) or percentage MVA (r2<0.13).
Conclusion:
Functional US perfusion parameters do not correlate with current histologic indices for quantifying angiogenesis. MVD, as a histologic quantitative measurement of angiogenesis, may not be an appropriate standard for contrast-enhanced imaging that relies on perfused neovessels.
Citing Articles
Assessment of angiogenesis in rabbit orthotropic liver tumors using three-dimensional dynamic contrast-enhanced ultrasound compared with two-dimensional DCE-US.
Zheng Q, Zhang J, Wang Z, Ruan S, Li W, Pan F
Jpn J Radiol. 2019; 37(10):701-709.
PMID: 31401722
DOI: 10.1007/s11604-019-00861-z.
Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.
Jing Y, Xiu-Juan Z, Hong-Jiao C, Zhi-Kui C, Qing-Fu Q, En-Sheng X
J Cancer Res Clin Oncol. 2019; 145(5):1191-1200.
PMID: 30805775
DOI: 10.1007/s00432-019-02866-7.
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
Amadori M, Barone D, Scarpi E, Oboldi D, Amadori E, Bandi G
Eur Radiol. 2018; 28(7):2969-2978.
PMID: 29417252
DOI: 10.1007/s00330-017-5254-5.
Hyposialylated IgG activates endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance.
Tanigaki K, Sacharidou A, Peng J, Chambliss K, Yuhanna I, Ghosh D
J Clin Invest. 2017; 128(1):309-322.
PMID: 29202472
PMC: 5749535.
DOI: 10.1172/JCI89333.
Angiogenesis in Ischemic Stroke and Angiogenic Effects of Chinese Herbal Medicine.
Seto S, Chang D, Jenkins A, Bensoussan A, Kiat H
J Clin Med. 2016; 5(6).
PMID: 27275837
PMC: 4929411.
DOI: 10.3390/jcm5060056.
RGD-Targeted Ultrasound Contrast Agent for Longitudinal Assessment of Hep-2 Tumor Angiogenesis In Vivo.
Hu Q, Wang X, Kang L, Wei H, Xu C, Wang T
PLoS One. 2016; 11(2):e0149075.
PMID: 26862757
PMC: 4749330.
DOI: 10.1371/journal.pone.0149075.
Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis.
Saini R, Hoyt K
Imaging Med. 2014; 6(1):41-52.
PMID: 25221623
PMC: 4160124.
DOI: 10.2217/iim.13.74.
Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Mancini M, Greco A, Salvatore G, Liuzzi R, Di Maro G, Vergara E
BMC Med Imaging. 2013; 13:31.
PMID: 24028408
PMC: 3848463.
DOI: 10.1186/1471-2342-13-31.
Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model.
Hoyt K, Sorace A, Saini R
J Ultrasound Med. 2012; 31(11):1759-66.
PMID: 23091246
PMC: 3560397.
DOI: 10.7863/jum.2012.31.11.1759.
Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
Zhu X, Zhang J, Fan P, Xiong Y, Zhuang P, Zhang W
BMC Cancer. 2011; 11:28.
PMID: 21251271
PMC: 3033852.
DOI: 10.1186/1471-2407-11-28.
Contrast enhanced maximum intensity projection ultrasound imaging for assessing angiogenesis in murine glioma and breast tumor models: A comparative study.
Forsberg F, Ro R, Fox T, Liu J, Chiou S, Potoczek M
Ultrasonics. 2010; 51(3):382-9.
PMID: 21144542
PMC: 3030198.
DOI: 10.1016/j.ultras.2010.11.004.
Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.
Blair B, Larson C, Adams P, Abada P, Pesce C, Safaei R
Mol Pharmacol. 2010; 79(1):157-66.
PMID: 20930109
PMC: 3014285.
DOI: 10.1124/mol.110.068411.
A method for assessing the microvasculature in a murine tumor model using contrast-enhanced ultrasonography.
Loveless M, Li X, Huamani J, Lyshchik A, Dawant B, Hallahan D
J Ultrasound Med. 2008; 27(12):1699-709.
PMID: 19022995
PMC: 2649799.
DOI: 10.7863/jum.2008.27.12.1699.
Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma model.
Seiler G, Ziemer L, Schultz S, Lee W, Sehgal C
Cancer Imaging. 2007; 7:216-23.
PMID: 18083651
PMC: 2151329.
DOI: 10.1102/1470-7330.2007.0031.
Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography.
Lyshchik A, Fleischer A, Huamani J, Hallahan D, Brissova M, Gore J
J Ultrasound Med. 2007; 26(11):1575-86.
PMID: 17957052
PMC: 2634836.
DOI: 10.7863/jum.2007.26.11.1575.